The present invention relates to a medical diagnostic device with a cellular biosensor which detects urea and uric acid by means of a synthetic genetic circuit essentially consisting of transcriptional regulator and bio-sensing module.

The present invention relates to a medical diagnostic device with a cellular biosensor which detects urea and uric acid by means of a synthetic genetic circuit essentially consisting of transcriptional regulator and bio-sensing module.

The present invention relates to a kit for the detection of urease and to a tool and a composition forming part of the kit. In particular, the present invention relates to a kit for the detection of urease which comprises a composition containing an indicator; a delivery tool arranged to deliver a tissue sample into contact with the composition; and urea carried on the delivery tool, whereby the urea is arranged to be delivered to the composition together with the tissue sample.

The present invention relates to a kit for the detection of urease and to a tool and a composition forming part of the kit. In particular, the present invention relates to a kit for the detection of urease which comprises a composition containing an indicator; a delivery tool arranged to deliver a tissue sample into contact with the composition; and urea carried on the delivery tool, whereby the urea is arranged to be delivered to the composition together with the tissue sample.

A urine analysis device includes a case configured to be positioned entirely within a toilet, the case having a front face for receiving a stream of urine directly from a user urinating on the toilet a rear face opposite the front face, and a collection port, disposed on either the front face or the rear face, wherein the case contains a test assembly configured to perform an analysis on urine collected through the collection port.

The present disclosure relates to the development of novel immunoassays for the detection of SARS-CoV-2 or secreted spike protein (or fragments thereof) in saliva, nasal mucosal sample, throat samples, or nasopharyngeal samples.

The present disclosure relates to the development of novel immunoassays for the detection of SARS-CoV-2 or secreted spike protein (or fragments thereof) in saliva, nasal mucosal sample, throat samples, or nasopharyngeal samples.

A method for determining in a sample, by mass spectrometry, the amount of one or more analytes selected from the group consisting of N-acetylthreonine, TMAP, phenylacetylglutamine, tryptophan, creatinine, meso-erythritol, arabitol, myo-inositol, N-acetyl serine, N-acetylalanine, 3-methylhistidine, trans-4-hydroxyproline, kynurenine, urea, C-glycosyltryptophan, 3-indoxyl sulfate, pseudouridine, and combinations thereof is described. The method comprises subjecting the sample to an ionization source under conditions suitable to produce one or more ions detectable by mass spectrometry from each of the one or more of the analytes; measuring, by mass spectrometry, the amount of the one or more ions from each of the one or more analytes; and using the measured amount of the one or more ions to determine the amount of each of the one or more analytes in the sample. Also described is a kit comprising one or more isotopically labeled analogues as internal standards for each of the one or more analytes.

A method for determining in a sample, by mass spectrometry, the amount of one or more analytes selected from the group consisting of N-acetylthreonine, TMAP, phenylacetylglutamine, tryptophan, creatinine, meso-erythritol, arabitol, myo-inositol, N-acetyl serine, N-acetylalanine, 3-methylhistidine, trans-4-hydroxyproline, kynurenine, urea, C-glycosyltryptophan, 3-indoxyl sulfate, pseudouridine, and combinations thereof is described. The method comprises subjecting the sample to an ionization source under conditions suitable to produce one or more ions detectable by mass spectrometry from each of the one or more of the analytes; measuring, by mass spectrometry, the amount of the one or more ions from each of the one or more analytes; and using the measured amount of the one or more ions to determine the amount of each of the one or more analytes in the sample. Also described is a kit comprising one or more isotopically labeled analogues as internal standards for each of the one or more analytes.

Apparatus and methods for measuring a concentration of a target molecule from a biological sample are disclosed. In one example, the apparatus includes a porous pad, which is impregnated with a solution containing at least one agent and which contains an unfilled capillary matrix, a housing for the porous pad, and a membrane that covers the porous pad.